Response Zoladex therapy metastatic prostate carcinoma Serum testosterone prostate-specific antigen PSA levels patients Stage prostate cancer discontinuation long-acting LHRH agonist goserelin acetate Zoladex patients goserelin acetate ten sixteen thirty months drug progressive metastatic disease patients PSA testosterone levels goserelin acetate patients testosterone level normal levels bilateral orchiectomy sixty days drug cases PSA testosterone levels castration PSA levels weeks orchiectomy patients findings suppression testosterone LHRH agonists permanent tumor progression suppression beneficial 